Filing summary
Entity discrepancy: The supplied filing is Frequency Therapeutics, Inc. (Nasdaq: FREQ), not Korro Bio, Inc. It is a Form 10-Q for the quarter ended June 30, 2021, filed August 12, 2021. Financial figures below are in U.S. dollars; amounts are rounded to millions unless stated otherwise.
Business context and reporting period
Frequency was a clinical-stage biotechnology company developing progenitor cell activation (PCA) therapies. Its lead candidate, FX-322, was being studied for sensorineural hearing loss (SNHL); the company also had preclinical research programs, including one for multiple sclerosis. It had no approved products and had not generated product-sales revenue.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $9.4 million | $8.5 million | $14.1 million | $15.8 million |
| Research and development expense | $17.4 million | $8.8 million | $32.5 million | $15.4 million |
| General and administrative expense | $9.5 million | $6.0 million | $19.2 million | $12.2 million |
| Net loss | $17.7 million | $6.0 million | $38.0 million | $10.9 million |
| Basic and diluted loss per share | $0.52 | $0.19 | $1.11 | $0.35 |
| Net cash used in operating activities | Not presented separately | Not presented separately | $43.1 million | $19.6 million |
- Revenue was recognized from the $80 million Astellas upfront payment, rather than product sales. The company completed its associated FX-322 Phase 2a performance obligation in June 2021 and recognized the remaining deferred revenue; no deferred revenue remained at June 30.
- At June 30, cash and cash equivalents were $135.0 million, with $40.5 million in marketable securities. The company reported total assets of $220.2 million, total liabilities of $54.2 million, and an accumulated deficit of $133.4 million.
- Debt included a $15 million term loan. Its stated interest rate was 4.75%; interest-only payments continue through November 2022, followed by principal and interest installments through May 2024. Lease liabilities totaled $31.4 million.
- Six-month investing cash outflow was $43.1 million, largely reflecting purchases of marketable securities and property and equipment. Cash, cash equivalents, and restricted cash declined by $85.3 million in the period.
- Management cited cash, cash equivalents, and short-term investments of $175.5 million and estimated these resources would fund operating expenses and capital needs into 2023, subject to assumptions that could prove incorrect.
Material changes versus prior comparable periods
- Q2 revenue increased 10% year over year, but six-month revenue declined 11%, reflecting the timing of recognition of the Astellas upfront payment. That revenue source was fully recognized by June 30, 2021.
- Six-month R&D expense more than doubled year over year, and G&A expense rose 58%. Management attributed increases principally to higher staffing and stock-based compensation, outsourced research, FX-322 development, and facility costs following the move to Lexington.
- Six-month net loss increased to $38.0 million from $10.9 million, while operating cash use increased to $43.1 million from $19.6 million. The company also began incurring term-loan interest expense in 2021.
Outlook, commentary, risks, and unusual items
- Final results from FX-322 Phase 2a (FX-322-202) showed that four weekly injections did not improve hearing measures versus placebo. The company reported an unexpectedly large increase in placebo-group word-recognition scores, which it said limited interpretation of that measure. Safety and tolerability were described as favorable.
- In a separate Phase 1b study (FX-322-111), 34% of 32 participants completing follow-up had at least a 10% absolute improvement in word-recognition scores in the treated ear at day 90; the filing reports statistical significance versus the untreated ear. The presbycusis study (FX-322-112) did not show a significant treatment effect versus placebo, though safety and tolerability were favorable.
- The severe-SNHL Phase 1b study (FX-322-113) was fully enrolled with 31 participants; topline results were expected in Q4 2021. In August 2021, the company announced plans to start a Phase 2 FX-322 trial in Q4 2021, using a single administration and a refined population and study design intended to address bias.
- The company expected R&D and G&A spending to continue increasing. It said additional financing would be needed over time; future funding could involve equity or debt, collaborations, or licensing, and might not be available on acceptable terms.
- Key risks include clinical and regulatory uncertainty, dependence on FX-322 and third-party manufacturers and research organizations, possible COVID-19-related trial or supply disruptions, competition, and the need for future capital. The Astellas agreement provides potential development milestones of up to $230 million, commercial milestones of up to $315 million, and tiered royalties, but these amounts depend on future development and commercial success.
- Two putative securities class actions filed in June 2021 allege misleading disclosures about FX-322 Phase 2a; the company said it was vigorously defending them and could not estimate a possible loss. A separate Delaware stockholder lawsuit seeks monetary damages; the company had moved to dismiss and also could not estimate a possible loss. No accruals were recorded for these matters at June 30.
- The company reported effective disclosure controls as of June 30, 2021 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing belongs to Frequency Therapeutics, not Korro Bio, before associating these results with the requested company.
- Review the final FX-322-202 data and the design, endpoints, and subsequent results of the planned Phase 2 and FX-322-113 studies.
- Assess the cash runway against actual operating cash use, trial costs, and the company’s assumptions underlying its estimate of funding into 2023.
- Confirm the implications of the completed Astellas upfront-payment revenue recognition and the conditions for any future milestone or royalty revenue.
- Monitor the securities and Delaware litigation for developments, potential financial exposure, and effects on management resources.